Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer
This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), June 2007
Sponsors and Collaborators: Fox Chase Cancer Center
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00450424
  Purpose

RATIONALE: The use of a CD-ROM may help patients with colorectal cancer or a family history of colorectal cancer make informed decisions about undergoing microsatellite instability (MSI) testing.

PURPOSE: This randomized phase I/II trial is studying an educational CD-ROM to see how well it works compared with standard informed consent to assist decision-making about MSI testing in patients with colorectal cancer or a family history of colorectal cancer.


Condition Intervention Phase
Colorectal Cancer
Hereditary Non-Polyposis Colon Cancer (hmsh2, hmlh1, hpms1, hpms2)
Procedure: counseling
Procedure: educational intervention
Procedure: immunohistochemistry staining method
Procedure: laboratory biomarker analysis
Procedure: microsatellite instability analysis
Procedure: mutation analysis
Procedure: polymerase chain reaction
Phase I
Phase II

Genetics Home Reference related topics: Lynch syndrome
MedlinePlus related topics: Cancer Colorectal Cancer
U.S. FDA Resources
Study Type: Interventional
Study Design: Randomized
Official Title: Facilitating Informed Decisions for MSI Testing

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Impact of standard informed consent vs CD-ROM educational intervention on knowledge about microsatellite instability (MSI) testing [ Designated as safety issue: No ]
  • Patient satisfaction with the preparation to make a decision [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Differential impact of CD-ROM on satisfaction with MSI test decision, difficulty making decision & decisional conflict; attitude; general & cancer-related distress; discussions with family about MSI test & familial colorectal cancer risk [ Designated as safety issue: No ]
  • Impact of demographic factors, disease/family history characteristics, family support, and cancer-related distress on satisfaction with and completeness of the informed consent process [ Designated as safety issue: No ]

Estimated Enrollment: 184
Study Start Date: June 2005
Detailed Description:

OBJECTIVES:

Primary

  • Compare the impact of standard informed consent vs a CD-ROM educational intervention on knowledge about microsatellite instability (MSI) testing in patients with colorectal cancer (CRC) or a family history of CRC.
  • Determine the impact of these interventions on patient satisfaction with the preparation to make a decision.

Secondary

  • Determine whether the CD-ROM educational intervention has a differential impact on satisfaction with the MSI test decision, difficulty making the MSI test decision, and decisional conflict, as well as on patients' attitudes about MSI testing and CRC (e.g., perceived benefits and barriers to having the MSI test, perceived risk for colorectal and related cancers, self-efficacy), on general and cancer-related distress, and on discussions with family members about the MSI test and familial CRC risk.
  • Assess whether demographic factors, disease/family history characteristics, family support for testing, and cancer-related distress moderate the impact of the intervention on satisfaction with and completeness of the informed consent process.

OUTLINE: This is a multicenter, pilot, phase I study followed by a randomized, phase II study.

  • Phase I: The educational CD-ROM is developed over 9 months. Patients receive a pilot version of the CD-ROM and provide feedback regarding usability and content.
  • Phase II: Patients are randomized to 1 of 2 arms.

    • Arm I: Patients complete a baseline interview and receive a standard informed consent for microsatellite instability (MSI) testing and a brief, standardized explanation of the MSI test.
    • Arm II: Patients complete a baseline interview and receive a standard informed consent for MSI testing and the educational CD-ROM developed in phase I.

All patients in phase II (even those that did not consent to the MSI test) complete a follow-up survey at 2 weeks.

Tissue samples from patients are analyzed by immunohistochemistry and MSI assay (polymerase chain reaction) for MLH1 and MSH2.

PROJECTED ACCRUAL: A total of 184 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Patient or family member meeting 1 of the following revised Bethesda colorectal cancer (CRC) criteria:

    • Diagnosis of colon or rectal cancer at < 50 years of age
    • Diagnosis of > 1 CRC at one time in the past
    • Diagnosis of ≥ 1 CRC at different times
    • Diagnosis of CRC and any other hereditary nonpolyposis colorectal cancer (HNPCC)-related cancers
    • Diagnosis of CRC in ≥ 2 first-degree or second-degree relatives with HNPCC-related tumor and ≥ 1 cancer diagnosed at < 50 years of age
    • Diagnosis of CRC in ≥ 2 first- or second-degree relatives with HNPCC-related tumors, regardless of age
    • Diagnosis of CRC with pathologic features suggestive of microsatellite instability (MSI) and < 60 years of age
  • Patients with CRC meeting the Amsterdam criteria defined below are ineligible:

    • Three relatives with CRC with 1 being a first-degree relative of the other 2
    • Cases that span ≥ 2 generations
    • At least 1 CRC case diagnosed before 50 years of age

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00450424

Locations
United States, Delaware
Helen F. Graham Cancer Center at Christiana Hospital Recruiting
Newark, Delaware, United States, 19713
Contact: Clinical Trials Office - Helen F. Graham Cancer Center     302-733-6227        
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Clinical Trials Office - Massachusetts General Hospital     877-726-5130        
United States, Pennsylvania
Fox Chase Cancer Center - Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19111-2497
Contact: Clinical Trials Office - Fox Chase Cancer Center - Philadelphi     215-728-4790        
Sponsors and Collaborators
Fox Chase Cancer Center
Investigators
Principal Investigator: Sharon Manne, PhD Fox Chase Cancer Center
  More Information

Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

Study ID Numbers: CDR0000443988, FCCC-04827
Study First Received: March 20, 2007
Last Updated: October 8, 2008
ClinicalTrials.gov Identifier: NCT00450424  
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
colon cancer
rectal cancer
hereditary non-polyposis colon cancer (hMSH2, hMLH1, hPMS1, hPMS2)
recurrent colon cancer
stage I colon cancer
stage II colon cancer
stage III colon cancer
stage IV colon cancer
recurrent rectal cancer
stage I rectal cancer
stage II rectal cancer
stage III rectal cancer
stage IV rectal cancer

Study placed in the following topic categories:
Metabolic Diseases
Digestive System Neoplasms
Rectal Neoplasms
Gastrointestinal Diseases
Colonic Diseases
Hereditary nonpolyposis colon cancer
Intestinal Diseases
Rectal Diseases
Recurrence
Intestinal Neoplasms
Rectal neoplasm
Neoplastic Syndromes, Hereditary
Digestive System Diseases
Genetic Diseases, Inborn
Colorectal Neoplasms, Hereditary Nonpolyposis
Gastrointestinal Neoplasms
Metabolic disorder
Rectal cancer
Colonic Neoplasms
Colorectal Neoplasms

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site
DNA Repair-Deficiency Disorders

ClinicalTrials.gov processed this record on January 14, 2009